First patient receives new engineered mRNA epigenetic
European Pharmaceutical Review
OCTOBER 28, 2022
revealed the first patient to be dosed with OTX-2002, the first programmable mRNA therapeutic for c-Myc (MYC) oncogene overexpression, which targets cancer cells while sparing healthy cells. OTX-2002 is delivered via lipid nanoparticles (LNPs) and controls the expression of specific genes using epigenetics, a new era of medicine. .
Let's personalize your content